Targeting Alpha-Synuclein in Parkinson’s Disease

Summary

In this episode of the Talking Biotech Podcast, Dr. Matthew Disney discusses the potential of RNA as a therapeutic target, exploring its historical context, pathogenic roles in diseases, and the challenges and innovations in drug design. The conversation delves into specific diseases like myotonic dystrophy, ALS, and various cancers, highlighting the advantages of small molecules in treatment and the future directions of RNA therapeutics.